Presenters
Course Details
Hypertension is a common cause of chronic kidney disease (CKD) in the Philippines and the presence of CKD can complicate the management of hypertension in these patients. In this episode of Hypertension Weekly Practice Webisodes of the Philippine Society of Hypertension, Dr. Lynn Almazan-Gomez (Asian Hospital and Medical Center) talked about the general principles of hypertension management in patients with CKD and the role of RAAS blockade. Dr. Richard Henry Tiongco II (UP-PGH) then discussed the role of ARBs in the prevention of adverse cardiovascular and renal outcomes in patients with hypertension and CKD.
1 CPD Point upon completion.
About the speakers
Dr. Lynn Almazan-Gomez is the Chief of the Section of Nephrology of the Asian Hospital and Medical Center. She is also a Clinical Associate Professor of the University of the Philippines – Philippine General Hospital (UP-PGH).
Dr. Richard Henry Tiongco II is an Associate Professor 7 at the UP College of Medicine Department of Pharmacology & Toxicology and a Clinical Associate Professor in cardiology at the UP-PGH.
Estimated time of Completion: 1 hr. 39 mins. 12 sec.
CPD Points: 1 Point
PRC Program No: PROG-2022-41420
PSH Webisode Series: Hypertension in CKD Course Outline
Dr. Lynn Gomez – RAAS Blockade in Hypertensive patients with CKD
- Historical Perspective of the RAAS System
- RAAS and downstream hormonal effects
- RAAS blockade – foundation of therapy in hypertensive patients with CKD (proteinuria reduction, CV protection and Renal protection)
- Tight vs. Standard BP target: similar improvement in CV Disease and slightly lower all-cause mortality (SPRINT)
- When is GFR too low not to give RAAS blockers
- Should we stop RAAS blockers once patients hit CKD 4-5
Dr. Ricard Henry Tiongco II – 2017 Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- Prevalence of cardiovascular disease in people with normal kidney function and patients with chronic kidney disease (based on 2018 USA data)
- 2020 ISH Simplified Classification of Hypertension Risk
- Initiation of antihypertensive treatment
- Telmisartan
- Unique “delta lock” structure of Telmisartan
- Pharmacological Profile of Telmisartan
- The Trough/Peak Ratio
- Telmisartan’s Long Duration of Effect
Dr. Ricard Henry Tiongco II – 2017 Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- ONTARGET (The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
- Telmisartan is as effective as Ramipril in Preventing CV Events at Increased CV Risk
- Telmisartan vs. Ramipril in renal Endothelial Dysfunction study
- Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study
- Telmisartan (80 mg) vs Losartan (100 mg) in hypertensive type-2 Diabetic patients with overt nephropathy
- INNOVATION: Transition from incipient to overt nephropathy and remission of albuminuria in T2DM
- Telmisartan is efficient along the renal continuum
PC-PH-103113 / December 2021